FDA
-
-
-
-
-
-
-
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
-
-
-
-
-
-
-
Tonix gets FDA clearance for major depression study of TNX-102 SL
-
-
-
-
-
-
-
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ
-
-
-
-
-
-
-
Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025
-
-
-
-
-
-
-
Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026
-
-
-
-
-
-
-
Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025
-
-
-
-
-
-
-
Tonix presents data on mpox and smallpox vaccine candidate at Vienna congress
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

